Use of FVIIa or FVIIai for the treatment of adverse conditions associated with FVIIa-mediated intracellular signaling pathway

摘要

The present invention provides methods for identifying candidate drugs that modulate factor VIIa-mediated intracellular signaling by measuring the effects of such drugs on the activation of the mitogen-activated protein kinase (MAP kinase) signaling pathway.